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parameters accordingly and any quality assurance checks that 
are deemed necessary. Therefore the adaptive radiation 
therapy requires more resources when compare to the 
conventional image-guided radiation therapy. In fact, image-
guidance can be considered the first step in adaptive practice 
as it triggers the initial decision to adapt and provide the 3D 
volumetric images that are necessary for adaptive re-plan. 
There have been efforts to create techniques and 
technologies that can facilitate the adaptive planning. In this 
presentation, we will first discuss the state of art practice of 
adaptive proton therapy including the experience at our 
institution. We will review studies assessing the magnitude of 
intra- and inter-fractional changes and its impact on 
delivered proton dose distribution with and without adaptive 
practice. Secondly, we will present the cutting edge ideas 
and techniques that are developed specifically for adaptive 
proton lung therapy in the most recent literature.  
[1] Liu HH, Balter P, Tutt T, et al. Assessing respiration-
induced tumor motion and internal target volume using 4DCT 
for radiation therapy of lung cancer. Int J Radiat Oncol Biol 
Phys 2007;68:531-540  
[2] Sonke JJ, Belderbos J. Adaptive Radiotherapy for lung 
cancer. Semin Radiat Oncol 2010 Apr; 20(2):94-106. 
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The finite range of protons is a two-edged sword. On one 
side, it is the raison d’etre of proton therapy, on the other, a 
potential source of uncertainties in-vivo. As such, both in-
vivo range estimates and adaptive therapy are being 
proposed and pursued for mitigating such uncertainties. 
However, sources of in-vivo range uncertainties are many, 
ranging from systematic uncertainties in the calibration of CT 
Hounsfield units to proton stopping power and inaccuracies in 
dose calculations (for convenience defined here as type I 
uncertainties) to variations in patient positioning and 
anatomy changes during the course of treatment (type 2). 
Whereas, for good quality CT data, type 1 uncertainties can 
result in range uncertainties of a few percent or millimeters 
(about 3% or 6mm in the worst case,) type 2 can result in 
range changes of the order of centimeters. In addition, type 
1 uncertainties will, to a good approximation, be similar 
across all patients of a particular indication and will remain 
the same throughout the duration of a patient’s treatment. 
Type 2 on the other hand will be patient and (potentially) 
treatment day dependent. So, what are the roles of in-vivo 
range measurement and adaptive therapy for dealing with 
these? It seems to this author that in-vivo range verification 
perhaps has a role to play in reducing type 1 uncertainties, 
whereas the best approach to type 2 has to be adaptive 
therapy. Adaptive therapy (based on regular, if not daily, 
imaging) must be pro-active (i.e. the treatment should 
ideally be adapted before delivery), whereas in-vivo range 
verification can only be (at best) reactive (e.g. may be able 
to provide a reason to interrupt a delivery if an error is 
detected). As such, the best use of in-vivo range estimation 
seems to be as part of a population based (commissioning) 
approach in order to verify that CT calibration and dose 
calculations are more and more precise, such that type 1 
uncertainties resulting from pre-treatment imaging 
(necessary to mitigate type 2 errors) can then be reduced as 
much as possible. Such an approach however puts stringent 
demands on the accuracy and precision of in-vivo range 
estimates, with in-vivo resolutions in the millimeter range 
being required in order to significantly improve these 
uncertainties. Will this ever be achievable?  
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One of the most exciting areas of basic, translational and 
clinical research in radiation oncology today is radiotherapy 
with particles, i.e. with protons or heavier ions. The main 
advantage of radiotherapy with protons compared to state-
of-the-art radiotherapy with photons is a decrease of the 
volume of normal tissues irradiated to intermediate and low 
doses, while irradiation of normal tissues to high doses or the 
conformality of the dose to the tumor are usually similar for 
protons and photons. Exceptions include situations where 
critical normal tissues can be excluded by proton therapy 
from the irradiated volume completely or to a large extent. 
The most relevant clinical research question is therefore to 
investigate whether sparing of normal tissue by proton 
therapy leads to clinical relevant benefits which balance the 
higher costs of this treatment. After demonstration of 
relevant sparing of normal tissues, further clinical studies on 
utilizing dose intensification strategies may become another 
important research avenue in those tumors where local or 
locoregional tumor control today are unsatisfactory. 
At present only few centers (often with different 
technologies and patient populations) are active in clinical 
research using protons, which makes fresh thinking on study 
design in radiation oncology necessary, as large scale 
randomized trials will not be feasible in many situations. 
Model-based approaches are a major component of the trial 
methodological portfolio, but alternatives (including 
multicenter stepwise randomized trials, pseudo-randomized 
trials and prospective matched pair trials) may be superior in 
different clinical situations. All of these approaches 
necessitate dedicated clinical research infrastructures and 
complex high-level network formation to reach the power for 
meaningful clinical trials. This also plays an important role in 
terms of radiotherapy stratified by biological parameters, 
which is anticipated to become a clinical reality in the near 
future for several tumor entities. 
Proton (or other particle) therapy holds particular promise to 
further advance personalized radiation oncology. However 
obstacles in trial design, data sampling and integration, or 
analysis may dilute the effects to such an extent that it may 
not be possible to demonstrate it according to generally 
accepted scientific standards. This would be a major hurdle 
for further implementation and reimbursement of this 
auspicious technology, and also for sound medical 
stratification of access of patients in need for this therapy. 
The lecture will discuss opportunities and problems of proton 
therapy in the context of high precision personalized as well 
as biologically stratified radiation oncology, thereby also 
touching trial design, technology development and the 
importance of network formation on a European level. 
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Small animal image guided irradiation platforms are 
revolutionizing the field of preclinical radiobiology by 
facilitating the delivery of clinically relevant irradiation 
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protocols under experimental conditions. Our laboratory is 
developing an in vivo radiobiology research program using the 
small animal radiotherapy research platform (SARRP, Xstrahl 
Life Sciences) as a central enabling technology to perform 
translational studies focussing on biologically optimised 
radiotherapy, nanoparticle theranostics and novel 
combination treatments. A major challenge now facing 
investigators is how to correctly apply the technology to 
accurately model clinical scenarios in relevant small animal 
models so that it can be exploited to its full potential in 
driving translational studies with outcomes likely to impact 
current standard of care in radiation oncology.  
An overview of the current state-of-the-art in preclinical 
radiotherapy will be presented including recent 
developments such as integration of bioluminescence 
imaging, preclinical 4-D CBCT and Monte Carlo based dose 
calculation methods. Examples of innovative preclinical 
studies will be highlighted along with experience from our 
own laboratory from commissioning to experimental design 
and important considerations for the successful execution of 
hypothesis-driven investigations using small animal 
radiotherapy.  
Despite certain challenges, small animal radiotherapy has 
much potential to bridge the translational gap between basic 
radiobiology and radiotherapy. As the technology develops 
and investigators gain experience as multidisciplinary 
scientists, pre-clinical studies that increasingly replicate the 
clinical scenario will drive new approaches in radiobiology 
that should ultimately translate to human health gains. 
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Although advances with in-vitro cancer cell culture models 
have occurred recently, in vivo tumor models are still crucial 
for the study of novel radiation treatments. This is 
particularly important for radiation combination approaches 
that target tumor cell non-autonomous anti-cancer pathways 
such as the tumor microenvironment or the immune system. 
In addition, more sophisticated animal studies with radiation 
are now possible with the advent of technologies that 
integrate treatment planning, imaging, and radiation delivery 
capabilities such as with the small-animal radiation platform 
(SARRP; Fig 1).  
 
 
Tumor xenograft models using human-derived tumor models 
implanted into immune-deficient mice are a mainstay of pre-
clinical testing and discovery. Although the majority of in 
vivo studies involve immunocompromised mice, such as 
athymic, severe combined immune-deficiency (SCID) or NOD-
SCID mice, these models are less ideal with radiation studies 
because some of these mice have mutations in DNA response 
and repair pathways. The abnormal DNA repair mechanisms 
in these mice limit the applicability of results with 
radiosensitizers given the integral role of DNA damage to the 
biologic effect of radiation therapy. Furthermore, anti-tumor 
effects of radiation may be mediated by the immune system. 
As a result of these limitations, genetically engineered mouse 
models (GEMMs) are becoming more widely used in 
preclinical studies with and without radiation. “Co-clinical 
trials” that use GEMMs that faithfully replicate the 
mutational events observed in human cancers to conduct 
preclinical trials that parallel ongoing human phase I/II 
clinical trials have shown great promise in cancer. This 
presentation will review published and on-going pre-clinical 
studies targeting both cancer cell autonomous and cancer 
cell non-autonomous pathways utilizing the SARRP with both 
xenograft tumor models and GEMMs at Johns Hopkins.  
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Clinical research faces many problems, of which the 
availability of pre-clinical models that predict the human 
situation is one of the most important. Pre-clinical tumour 
models are being used for decades in many cases with the 
assumption that they are predictive for what will later 
happen in humans. As such, the use of pre-clinical, mostly 
mouse, models may limit the exposure of inactive and or 
toxic treatments in patients. Although there is no doubt that 
pre-clinical models have been crucial to understand better 
molecular and other characteristics of carcinogenesis, growth 
and metastases and were the basis of many currently used 
cancer therapies, they still have considerable shortcomings. 
Classical mouse models use tumour cell lines that have been 
grown in vitro for many years and hence may have altered 
characteristics compared to de novo tumours. These tumour 
cells are then implanted subcutaneously in mice and tend to 
grow rapidly and thus do not mimic the much slower doubling 
times of most human cancers. This faster tumour growth may 
lead to a higher sensitivity for most chemotherapy drugs and 
hence erroneous conclusions. Moreover, in some situations, 
ectopic (out of the normal place) subcutaneously implanted 
tumours — still a standard methodology — may respond 
differently to treatment compared to tumours grown in an 
orthotopic site, i.e. in their organ or tissue of origin, such as 
breast cancers in mammary fat pads. The latter may 
correspond more to the human situation. Moreover, 
metastases frequently show other responses than primary 
tumours in patients, and it is only recently that these effects 
can be mimicked in genetically engineered mouse models. 
Tumour bearing mice are often treated with drugs at levels, 
or with pharmacokinetics, that are not relevant to humans. 
Furthermore, nearly all pre-clinical models have not used 
tumours that were pre-exposed to another therapy, whereas 
in many phase I and phase II clinical trials only patients that 
show tumour progression after one or more systemic 
treatments are included. With the huge interest in immune 
therapy, the use of humanised mice has gained even more 
attention than before. However, these models still face 
problems with remaining mouse innate immunity and weak 
human innate and adaptive immunity. Even the best models 
suffer from the development of wasting disease in highly 
engrafted humanized mice and poorly developed lymph nodes 
and germinal centres. It is also unclear if the cell trafficking 
resembles that of humans.At present, no single mouse models 
mimics perfectly the human situation. However, models that 
use injected tumour cells in the organ from which they were 
derived and which form metastases in organs that are similar 
to the human situation may be the most appropriate for they 
bear a micro-environment that resembles that of humans. 
